UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
Item 2.02 |
Results of Operations and Financial Condition. |
On May 10, 2022, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|
Item 9.01 |
Financial Statements and Exhibits. |
Reference is made to the Exhibit Index attached hereto.
EXHIBIT INDEX
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
|
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
UNITY BIOTECHNOLOGY, INC. |
|
|
|
|
|
|
Date: May 10, 2022 |
By: |
/s/ Anirvan Ghosh |
|
|
|
Anirvan Ghosh, Ph.D. |
|
|
|
Chief Executive Officer |
Exhibit 99.1
UNITY Biotechnology, Inc. Reports First Quarter 2022
Financial Results and Business Updates
-Completed enrollment in BEHOLD, the Phase 2 clinical trial of UBX1325 in DME; BEHOLD remains on track with 12-week safety and efficacy data anticipated by mid-year 2022-
-Dosed first patient in ENVISION, the Phase 2 clinical trial of UBX1325 in wet age-related macular degeneration; ENVISION remains on track with 16-week results expected in Q4 2022-
-As of March 31, 2022, UNITY had approximately $79.2 million in cash, cash equivalents and marketable securities, extending runway through Q1 2023-
SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2022.
“The outset of 2022 was marked by important progress across our ongoing clinical development program for UBX1325, such as successfully completing enrollment for BEHOLD, our Phase 2 clinical trial of UBX1325 in patients with diabetic macular edema (DME), as well as initiating ENVISION, our Phase 2 clinical trial of UBX1325 in patients with wet age-related macular degeneration (wAMD),” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “We are encouraged by the growing evidence that underscores the role cellular senescence plays in ocular diseases, and believe we are well positioned to build on the results from the promising Phase 1 trial of UBX1325, which we recently presented at the ARVO 2022 Annual Meeting. Looking ahead, we remain on track to deliver on multiple upcoming catalysts, including 12-week data from our DME study by mid-year 2022. We are appreciative of the support and the enthusiasm we have received from patients and KOLs, and we will continue to deliver on our mission to address the urgent need for innovative therapeutic alternatives beyond anti-VEGFs for key ophthalmologic conditions.”
Upcoming Milestones
|
|
• |
UBX1325 12-week safety and efficacy data from BEHOLD, the Phase 2 DME clinical trial (UBX1325-02 Study) by mid-year 2022, as well as 24-week safety and efficacy data before year-end 2022 |
|
|
• |
UBX1325 16-week safety and efficacy data from ENVISION, the Phase 2 wAMD clinical trial (UBX1325-03 Study) expected in Q4 2022 |
|
|
• |
Tie2/VEGF bispecific preclinical data to support selection of advanced candidate by mid-year 2022 |
|
|
First Quarter Financial Results
Cash, cash equivalents and marketable securities totaled $79.2 million as of March 31, 2022, compared with $90.1 million as of December 31, 2021. UNITY believes that current cash, cash equivalents, and marketable securities are sufficient to fund operations through the first quarter of 2023.
Operating loss for the three months ended March 31, 2022, was $18.9 million compared to $15.8 million for the three months ended March 31, 2021. Cash used in operations during the first quarter of 2022 was $15.0 million compared to $15.1 million for the first quarter of 2021.
Research and development expenses increased by $3.8 million, to $12.5 million for the three months ended March 31, 2022, from $8.7 million for the three months ended March 31, 2021. The increase was primarily due to increases of $3.5 million in direct research and development expenses mainly due to the progress of UBX1325 studies and $1.2 million in personnel costs due to reduction in force and $0.4 million in retention bonus accruals, offset by decreases of $0.7 million in facilities-related costs due to allocation to general and administrative expenses of net expenses on Brisbane and East Grand facilities which have been subleased, $0.2 million in employee stock based compensation forfeited from the reduction in force and $0.4 million in laboratory supplies.
General and administrative expenses decreased by $0.4 million, to $5.8 million for the three months ended March 31, 2022, from $6.2 million for the three months ended March 31, 2021. The decrease was primarily due to decreases of $0.6 million in facilities-related costs, $0.3 million in recruitment expenses and $0.2 million in professional fees, offset by increases of $0.4 in personnel costs mainly due to reduction in force and $0.2 million in retention bonus accruals and $0.1 million in insurance expense.
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME, AMD, and other ophthalmologic diseases, the expected timing of enrollment and results of the clinical trials in UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITY’s understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of UNITY in general, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed with the Securities and Exchange Commission on May 10, 2022, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.
Unity Biotechnology, Inc.
Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
|
|
|
Three Months Ended |
|
|||||
|
|
March 31, |
|
||||||
|
|
|
2022 |
|
|
2021 |
|
||
|
|
|
(Unaudited) |
|
|||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
Research and development |
|
|
12,461 |
|
|
|
8,717 |
|
|
General and administrative |
|
|
5,806 |
|
|
|
6,226 |
|
|
Total operating expenses |
|
|
18,267 |
|
|
|
14,943 |
|
|
Loss from operations |
|
|
(18,267 |
) |
|
|
(14,943 |
) |
|
Interest income |
|
|
29 |
|
|
|
36 |
|
|
Interest expense |
|
|
(808 |
) |
|
|
(775 |
) |
|
Other income (expense), net |
|
|
131 |
|
|
|
(74 |
) |
|
Net loss |
|
|
(18,915 |
) |
|
|
(15,756 |
) |
|
Other comprehensive (loss) gain |
|
|
|
|
|
|
|
|
|
Unrealized (loss) gain on marketable debt securities |
|
|
(132 |
) |
|
|
10 |
|
|
Comprehensive loss |
|
$ |
(19,047 |
) |
|
$ |
(15,746 |
) |
|
Net loss per share, basic and diluted |
|
$ |
(0.28 |
) |
|
$ |
(0.29 |
) |
|
Weighted-average number of shares used in computing net loss per share, basic and diluted |
|
|
67,528,552 |
|
|
|
54,169,349 |
|
Unity Biotechnology, Inc.
Condensed Balance Sheets
(In thousands)
|
|
|
March 31, |
|
|
December 31, |
|
||
|
|
|
2022 |
|
|
2021 |
|
||
|
|
|
(Unaudited) |
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
Current Assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
16,446 |
|
|
$ |
32,905 |
|
|
Short-term marketable securities |
|
|
62,717 |
|
|
|
55,170 |
|
|
Prepaid expenses and other current assets |
|
|
1,770 |
|
|
|
1,879 |
|
|
Restricted cash |
|
|
550 |
|
|
|
550 |
|
|
Total current assets |
|
|
81,483 |
|
|
|
90,504 |
|
|
Property and equipment, net |
|
|
9,308 |
|
|
|
9,942 |
|
|
Operating lease right-of-use assets |
|
|
20,706 |
|
|
|
21,286 |
|
|
Long-term marketable securities |
|
|
— |
|
|
|
1,993 |
|
|
Long-term restricted cash |
|
|
896 |
|
|
|
896 |
|
|
Other long-term assets |
|
|
76 |
|
|
|
91 |
|
|
Total assets |
|
$ |
112,469 |
|
|
$ |
124,712 |
|
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
3,323 |
|
|
$ |
1,985 |
|
|
Accrued compensation |
|
|
2,837 |
|
|
|
4,028 |
|
|
Accrued and other current liabilities |
|
|
6,692 |
|
|
|
6,370 |
|
|
Deferred revenue |
|
|
216 |
|
|
|
216 |
|
|
Derivative liability related to debt |
|
|
— |
|
|
|
963 |
|
|
Current portion of long-term debt |
|
|
4,837 |
|
|
|
3,055 |
|
|
Total current liabilities |
|
|
17,905 |
|
|
|
16,617 |
|
|
Operating lease liability, net of current portion |
|
|
29,339 |
|
|
|
30,094 |
|
|
Long-term debt, net |
|
|
14,534 |
|
|
|
18,409 |
|
|
Other long-term liabilities |
|
|
— |
|
|
|
23 |
|
|
Total liabilities |
|
|
61,778 |
|
|
|
65,143 |
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
|
|
|
Common stock |
|
|
7 |
|
|
|
6 |
|
|
Additional paid-in capital |
|
|
469,799 |
|
|
|
459,631 |
|
|
Accumulated other comprehensive loss |
|
|
(176 |
) |
|
|
(44 |
) |
|
Accumulated deficit |
|
|
(418,939 |
) |
|
|
(400,024 |
) |
|
Total stockholders’ equity |
|
|
50,691 |
|
|
|
59,569 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
112,469 |
|
|
$ |
124,712 |
|
Media
Canale Communications
Jason Spark
jason.spark@canalecomm.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com